$144 Million is the total value of Aisling Capital LLC's 5 reported holdings in Q1 2014. The portfolio turnover from Q4 2013 to Q1 2014 was - .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
MEIP | New | MEI Pharma, Inc. | $8,600,000 | – | 770,000 | +100.0% | 5.98% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2014-05-13
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
TRANSENTERIX INC. | 22 | Q3 2019 | 12.1% |
CHIMERIX INC. | 21 | Q4 2018 | 19.4% |
ADMA BIOLOGICS INC. | 20 | Q3 2019 | 35.5% |
LOXO ONCOLOGY INC. | 18 | Q4 2018 | 80.9% |
AIMMUNE THERAPEUTICS INC. | 17 | Q3 2019 | 68.7% |
CIDARA THERAPEUTICS INC. | 17 | Q3 2019 | 4.1% |
AGILE THERAPEUTICS INC. | 16 | Q1 2018 | 5.5% |
ZELTIQ AESTHETICS INC | 14 | Q3 2017 | 16.3% |
ESPERION THERAPEUTICS INC NE | 14 | Q3 2017 | 24.9% |
VERSARTIS INC | 13 | Q2 2017 | 16.2% |
View Aisling Capital LLC's complete holdings history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2019-11-13 |
13F-HR | 2019-08-08 |
13F-HR | 2019-05-07 |
13F-HR | 2019-02-11 |
13F-HR | 2018-11-05 |
13F-HR | 2018-08-13 |
13F-HR | 2018-05-14 |
13F-HR | 2018-02-07 |
13F-HR | 2017-11-09 |
13F-HR | 2017-08-14 |
View Aisling Capital LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.